Forecasts data is unavailable for this security.

Consensus recommendation

As of Jul 26, 2016, the consensus forecast amongst 25 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.
RecommendationsLatest
Buy7
Outperform8
Hold10
Underperform0
Sell0

Research reports

S&P Capital IQ – STARS Reports

Gilead Sciences
11 pages, 25 Jul 2016

Ford Investor Services, Inc.

More ▼

Share price forecast

The 18 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 106.50, with a high estimate of 135.00 and a low estimate of 80.00. The median estimate represents a 31.40% increase from the last price of 81.05.
High66.6%135.00
Med31.4%106.50
Low-1.3%80.00

Dividends

In 2015, Gilead Sciences Inc reported a dividend of 1.29 USD. The 12 analysts covering the company expect dividends of 1.85 USD for the upcoming fiscal year, an increase of 43.64%.
Div growth (TTM)--
More ▼

Earnings history & estimates

On Jul 25, 2016, Gilead Sciences, Inc. reported 2nd quarter 2016 earnings of 3.08 per share. This result was in line with the consensus of the 22 analysts following the company and under-performed last year's 2nd quarter results by 2.22%.
Average growth rate-0.44%
Gilead Sciences, Inc. reported annual 2015 earnings of 12.61 per share on Feb 02, 2016.
Average growth rate+89.52%
More ▼

Revenue history & estimates

Gilead Sciences Inc. had 2nd quarter 2016 revenues of 7.78bn. This bettered the 7.77bn consensus of the 19 analysts covering the company. This was 5.68% below the prior year's 2nd quarter results.
Average growth rate-1.36%
Gilead Sciences Inc. had revenues for the full year 2015 of 32.64bn. This was 31.13% above the prior year's results.
Average growth rate+46.12%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.